FRLN Freeline Therapeutics Holdings ADS

Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference

Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference

LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that senior management will participate in a Fireside Chat at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:50 pm EDT.

A webcast of the event will be available on the section of the Freeline website. Senior management will also participate in virtual one-on-one meetings with investors at the conference.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Contact

David S. Arrington

Vice President Investor Relations & Corporate Communications

Freeline Therapeutics



+1 (646) 668 6947 



EN
12/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports by Freeline Therapeutics Holdings ADS

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline Announces Executive Leadership Changes

Freeline Announces Executive Leadership Changes Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief Scientific Officer role on an interim basis to replace departing Chief Scientific Officer Romuald Corbau LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from in...

David Nierengarten
  • David Nierengarten
 PRESS RELEASE
FRLN Freeline Therap... (Health Care)

Freeline Reports First Quarter 2021 Financial Results and Recent Busin...

Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected to be in the clinic by year-end FLT180a Phase 1/2 dose-confirmation study in Hemophilia B on track to initiate trial sites by year-end LONDON, May 17, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch